Revenues were almost flat, at RON380 million.
The company does not specify what triggered the profit decline, but mentins that the over 5% inflation of the first six months impacted the consumption behavior. Also, market data pointed to a change in the prescription behavior, which the weight of original products in total consumption rising from 57% to 58% by value.
International sales revenues totaled RON138 million, down 7% from the first half of 2024. The company also tapped new markets, such as Italy, France, Poland and Czechia.
At the end of the first quarter, Antibiotice Iasi had a RON1.7 billion capitalization, after its shares have risen by 2% since the start of the year.
(English version by Catalina Apostoiu)